Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database

Table 4 Multivariable linear regression analysis of effect of baseline characteristics on HAQ-DI score progression at 1 year

	B	95% CI for B	p value
Constant	− 0.16	− 0.51, 0.20	0.389
HAQ-DI score at baseline	− 0.15	− 0.27, − 0.04	0.009
Age at onset of RP	− 0.002	− 0.01, 0.004	0.518
Male gender	0.02	− 0.18, 0.22	0.834
mRSS	0.01	0.0001, 0.03	0.048
Immunomodulator treatment	0.02	− 0.17, 0.20	0.870
Corticosteroids > 10 mg/day	0.12	− 0.77, 1.01	0.791
Advanced organ involvement^a	− 0.15	− 0.67, 0.37	0.575
Advanced lung involvement	0.05	− 0.55, 0.65	0.866
Advanced cardiac involvement	0.62	− 0.36, 1.60	0.213
Advanced GI involvement^b	0.40	− 0.20, 0.99	0.186
Advanced renal involvement	0.47	− 0.56, 1.50	0.367
Esophageal symptoms	0.33	0.14, 0.52	0.001
Stomach symptoms	− 0.04	− 0.25, 0.16	0.670
Intestinal symptoms	0.09	− 0.09, 0.26	0.335

CI confidence interval, GI gastrointestinal, HAQ-DI Health Assessment Questionnaire-Disability Index, mRSS modified Rodnan Skin Score, RP Raynaud’s phenomenon
^aInvolved organs coded as 0 = none, 1 = one organ involvement, 2 = multiple organ involvement
^bMalabsorption or ≥ 10% weight loss from baseline

ISSN: 1478-6362